Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really does help curb drinking ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted disease with increasing prevalence and profound ...